Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7724742 | 0.96 | EPHX2 (0.46) | EPHX2SMN1; SMN2KDM4ERAB9ANPC1 | |
| SCHEMBL7719578 | 0.91 | RAB9A (0.40) | EPHX2SMN1; SMN2KDM4ERAB9ANPC1 | |
| Fumaric Acid SCHEMBL7723100 | 0.91 | TAAR1 (0.48) | EPHX2SMN1; SMN2KDM4ERAB9ANPC1 | |
| Fumaric Acid SCHEMBL7723104 | 0.91 | TAAR1 (0.48) | EPHX2SMN1; SMN2KDM4ERAB9ANPC1 | |
| SCHEMBL7723864 | 0.90 | RAB9A (0.51) | SMN1; SMN2RAB9ANPC1CYP2C9CYP2C19 | |
| SCHEMBL7729374 | 0.86 | EPHX2 (0.54) | EPHX2SMN1; SMN2RAB9ANPC1CYP2C9 | |
| SCHEMBL7719562 | 0.85 | SMN1; SMN2 (0.49) | SMN1; SMN2RAB9ACYP2C9CYP2C19CYP2D6 | |
| SCHEMBL7722987 | 0.85 | NAMPT (0.45) | EPHX2SMN1; SMN2RAB9ANPC1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL7729370 | 0.84 | SMN1; SMN2 (0.48) | SMN1; SMN2RAB9ACYP2C9CYP2C19CYP2D6 | |
| SCHEMBL1678244 | 0.84 | HPGD (0.50) | EPHX2SMN1; SMN2KDM4ERAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6420398-B2 | FOR TREATING AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS; 4-(3-(2-(ACETYLTHIO)ETHYL)-3-(2-CYCLOHEXYLETHYL)-UREIDOMETHYL)-1 -METHYLPYRIDINIUM IODIDE, FOR EXAMPLE; INHIBIT PRODUCTION OF TUMOR NECROSIS FACTOR ALPHA (TNF-A) | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-07-16 | — | — | US | disclosed |
| US-20010041725-A1 | Novel urea derivatives having nitrogen aromatic heterocycle | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-11-15 | — | — | US | disclosed |
| EP-1103543-A1 | NOVEL UREA DERIVATIVES BEARING NITROGENOUS AROMATIC HETEROCYCLES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010041725-A1 | Novel urea derivatives having nitrogen aromatic heterocycle | TNF, UACA, HRH4 | EPHX2 1074/4885SMN1; SMN2 4609/4885KDM4E 1720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.